Spectral AI, Inc. (MDAI) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Spectral AI, Inc. is an emerging growth company and smaller reporting company focused on predictive medical diagnostics using its DeepView™ System. The system utilizes AI and multispectral imaging to assess burn wound healing potential. The company currently generates revenue primarily through government research and development contracts (BARDA, MTEC, DHA) and has not yet generated commercial product revenue. In June 2025, the company filed a De Novo application with the FDA for Class II medical device designation.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $5,065 | $7,478 | $11,772 | $13,804 |
| Gross Profit | $2,290 | $3,314 | $5,458 | $6,259 |
| Gross Margin | 45.2% | 44.3% | 46.4% | 45.3% |
| Operating Loss | $(2,123) | $(2,442) | $(3,019) | $(4,585) |
| Net Loss | $(7,968) | $(2,864) | $(5,071) | $(6,069) |
| Net Loss Per Share (Basic/Diluted) | $(0.31) | $(0.16) | $(0.21) | $(0.36) |
| Cash and Equivalents (End of Period) | $10,524 | $6,877 | $10,524 | $6,877 |
| Total Debt (Current + Long-Term) | $7,756 | $2,787 | $7,756 | $2,787 |
| Warrant Liabilities | $10,555 | $6,451 | $10,555 | $6,451 |
Note: Debt figures include current and long-term notes payable. Warrant liabilities are classified as liabilities and marked to market.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 32.3% in Q2 2025 compared to Q2 2024, and 14.7% on a year-to-date basis. This reflects reduced activity as the company completed work under the PBS BARDA Contract.
- Increased Net Loss: Net loss widened significantly in Q2 2025 ($7.97M) compared to Q2 2024 ($2.86M). The primary driver was a $5.45 million loss from the change in fair value of warrant liabilities, compared to a $348k gain in the prior year. This volatility stems from the re-pricing of Public Warrants in November 2024.
- Debt Financing: In March 2025, the company secured the "Avenue Financing," a credit facility allowing up to $15.0 million in borrowing with an initial draw-down of $8.5 million. This increased total debt significantly compared to the prior year.
- Cost Reductions: General and administrative expenses decreased 23.3% in Q2 2025, driven by reduced staffing and consulting costs as the company focused on the DeepView Burn application.
Guidance, Outlook, and Risks
- Liquidity: Management believes current cash ($10.5M), the Avenue Financing, and existing government contracts provide sufficient working capital for at least one year beyond the filing date.
- Regulatory Milestones: The company filed its FDA De Novo application in June 2025. A second tranche of $6.5 million in debt financing is contingent upon FDA clearance of the DeepView System and a $7.0 million equity raise.
- Commercialization: Initial sales in the UK are anticipated to begin in 2026 following UKCA authorization. The business model will transition to a SaaS (software licensing) and imaging device sales model upon commercial launch.
- Internal Controls: The company disclosed a material weakness in internal controls over financial reporting related to the financial statement close process, which has not yet been remediated. Disclosure controls and procedures were deemed ineffective as of June 30, 2025.
- Customer Concentration: The company is highly dependent on U.S. government agencies. One customer (BARDA) accounted for 92% of revenue in Q2 2025 and 94% of accounts receivable.
Investor Verification Checklist
- Warrant Liability Volatility: Verify the impact of the $10.5M warrant liability on net loss and the potential for future non-cash gains/losses based on stock price fluctuations.
- FDA De Novo Status: Monitor the status of the June 2025 FDA De Novo submission, as the second tranche of debt financing ($6.5M) is contingent on this approval.
- Internal Control Remediation: Review progress on remediation of the material weakness in financial reporting controls to assess reliability of future financial data.
- Government Contract Renewals: Assess the timeline and certainty of future funding from BARDA and MTEC, given the 92% revenue concentration in Q2 2025.
- Debt Covenants: Review the terms of the Avenue Financing, specifically the milestones required for the second tranche and the interest-only payment period.